Finally, a pooled analysis of 562 patients in three bladder cohorts (TCGA, DFCI, and BGI) showed that bladder carcinomas with ZFP36 gene family mutations were associated with better overall survival as compared to others (P = 0.01; Fig. 2h); we also observed a trend toward improved progression-free survival in these patients (P = 0.08; Fig. 2i). Here, ZFP36 is linked to urinary bladder carcinoma.